Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The decision was made to terminate the study after the completion of Phase 1 enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns.

Conditions

Metastatic Uveal Melanoma in the Liver

Interventions

DRUG: SD-101
BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab and Relatlimab

Sponsor

TriSalus Life Sciences, Inc.